OncoCyte (NYSEAMERICAN:OCX) PT Lowered to $6.00

OncoCyte (NYSEAMERICAN:OCX) had its target price reduced by Benchmark from $7.00 to $6.00 in a report issued on Thursday, BenzingaRatingsTable reports. They currently have a speculative buy rating on the biotechnology company’s stock.

OCX has been the topic of several other reports. Piper Sandler lowered OncoCyte from an overweight rating to a neutral rating in a research report on Tuesday, June 30th. Zacks Investment Research upgraded OncoCyte from a hold rating to a buy rating and set a $1.50 price objective on the stock in a report on Wednesday, July 15th. Needham & Company LLC initiated coverage on shares of OncoCyte in a research note on Tuesday, June 30th. They issued a buy rating and a $4.00 target price for the company. Lake Street Capital dropped their price target on shares of OncoCyte from $6.00 to $4.00 and set a buy rating on the stock in a research note on Tuesday, June 30th. Finally, Chardan Capital downgraded shares of OncoCyte from a buy rating to a neutral rating and cut their price target for the company from $7.75 to $2.00 in a report on Tuesday, June 30th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of $4.17.

OCX stock opened at $1.35 on Thursday. OncoCyte has a 52-week low of $1.20 and a 52-week high of $3.51.

OncoCyte (NYSEAMERICAN:OCX) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The business had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.04 million.

Several institutional investors have recently modified their holdings of OCX. Phoenix Holdings Ltd. bought a new stake in shares of OncoCyte during the 1st quarter worth $628,000. P.A.W. Capital Corp lifted its position in OncoCyte by 40.0% during the 1st quarter. P.A.W. Capital Corp now owns 350,000 shares of the biotechnology company’s stock worth $858,000 after acquiring an additional 100,000 shares during the last quarter. Private Wealth Partners LLC boosted its holdings in OncoCyte by 87.5% during the second quarter. Private Wealth Partners LLC now owns 150,000 shares of the biotechnology company’s stock valued at $287,000 after acquiring an additional 70,000 shares during the period. Penbrook Management LLC grew its position in shares of OncoCyte by 21.9% in the first quarter. Penbrook Management LLC now owns 215,625 shares of the biotechnology company’s stock valued at $529,000 after purchasing an additional 38,747 shares during the last quarter. Finally, Oxford Asset Management LLP bought a new position in shares of OncoCyte in the fourth quarter worth about $64,000.

OncoCyte Company Profile

OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.

Featured Story: Consumer Price Index (CPI)

Analyst Recommendations for OncoCyte (NYSEAMERICAN:OCX)

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.